CL2009001183A1 - Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico. - Google Patents
Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico.Info
- Publication number
- CL2009001183A1 CL2009001183A1 CL2009001183A CL2009001183A CL2009001183A1 CL 2009001183 A1 CL2009001183 A1 CL 2009001183A1 CL 2009001183 A CL2009001183 A CL 2009001183A CL 2009001183 A CL2009001183 A CL 2009001183A CL 2009001183 A1 CL2009001183 A1 CL 2009001183A1
- Authority
- CL
- Chile
- Prior art keywords
- types
- pharmaceutical formulation
- cilostazol
- pregelatinized starch
- solid pharmaceutical
- Prior art date
Links
- 229920000881 Modified starch Polymers 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 title 1
- 229960004588 cilostazol Drugs 0.000 title 1
- 150000007524 organic acids Chemical class 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulación farmacéutica sólida que comprende a) un ingrediente activo, b) 10 a 90% de un almidón pregelatinizado y c) uno o más tipos de ingredientes entéricos; y su método de preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008128259 | 2008-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001183A1 true CL2009001183A1 (es) | 2010-06-18 |
Family
ID=40847022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001183A CL2009001183A1 (es) | 2008-05-15 | 2009-05-14 | Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20110091535A1 (es) |
| EP (1) | EP2273981B1 (es) |
| JP (1) | JP5552434B2 (es) |
| KR (1) | KR101585280B1 (es) |
| CN (2) | CN104971037A (es) |
| AR (1) | AR071706A1 (es) |
| AU (1) | AU2009247156B2 (es) |
| BR (1) | BRPI0912656A2 (es) |
| CA (1) | CA2722244C (es) |
| CL (1) | CL2009001183A1 (es) |
| CO (1) | CO6321223A2 (es) |
| CY (1) | CY1115955T1 (es) |
| DK (1) | DK2273981T3 (es) |
| EA (1) | EA022712B1 (es) |
| EC (1) | ECSP10010683A (es) |
| ES (1) | ES2524261T3 (es) |
| HR (1) | HRP20141134T1 (es) |
| IL (1) | IL208788A (es) |
| MX (1) | MX2010012432A (es) |
| MY (1) | MY153109A (es) |
| NZ (1) | NZ588794A (es) |
| PE (2) | PE20140962A1 (es) |
| PL (1) | PL2273981T3 (es) |
| PT (1) | PT2273981E (es) |
| RS (1) | RS53775B1 (es) |
| SG (1) | SG190643A1 (es) |
| SI (1) | SI2273981T1 (es) |
| TW (1) | TWI501789B (es) |
| UA (1) | UA102547C2 (es) |
| WO (1) | WO2009139504A2 (es) |
| ZA (1) | ZA201008115B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101282847B1 (ko) * | 2011-07-27 | 2013-07-05 | 조선대학교산학협력단 | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 |
| TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
| CN103920156B (zh) * | 2014-04-04 | 2016-06-01 | 成都科特包衣技术有限公司 | 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法 |
| CN106511313B (zh) * | 2016-10-21 | 2019-06-07 | 浙江为康制药有限公司 | 西洛他唑缓释胶囊组合物及其制备方法 |
| EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
| WO2020218517A1 (ja) * | 2019-04-25 | 2020-10-29 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
| WO2025133928A2 (en) * | 2023-12-19 | 2025-06-26 | Angelini Pharma S.P.A. | Pharmaceutical matrices for prolonged drug release |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT8920486A0 (it) * | 1989-05-12 | 1989-05-12 | Isf Spa | Composizioni farmaceutiche. |
| US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| EG23951A (en) * | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
| JP4641696B2 (ja) * | 1999-09-30 | 2011-03-02 | 大塚製薬株式会社 | 消化管下部溶解性コーティング製剤 |
| JP4637338B2 (ja) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | シロスタゾール有核錠 |
| JP2002193792A (ja) * | 2000-12-25 | 2002-07-10 | Lion Corp | フィルムコーティング錠剤及びエロージョン防止組成物 |
| MXPA05004422A (es) * | 2002-10-25 | 2007-11-22 | Collegium Pharmaceutical Inc | Composiciones de milnacipran de liberacion pulsatil. |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| KR20050088190A (ko) * | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
| WO2005023225A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Cilostazol adsorbate |
| US20050255155A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Modified release cilostazol compositions |
| TWI338583B (en) * | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
| JP5112619B2 (ja) * | 2004-05-20 | 2013-01-09 | 大塚製薬株式会社 | 固形医薬製剤 |
| EP1945189A4 (en) * | 2005-11-03 | 2012-08-15 | Sun Pharmaceutical Ind Ltd | CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION |
| WO2007105229A1 (en) * | 2006-03-14 | 2007-09-20 | Panacea Biotec Ltd. | Controlled release pharmaceutical composition and process thereof |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| JP2010508266A (ja) * | 2006-10-30 | 2010-03-18 | ハナル ファーマシューティカル カンパニー リミテッド | チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物 |
| RU2465916C2 (ru) * | 2007-10-19 | 2012-11-10 | Оцука Фармасьютикал Ко., Лтд. | Твердый фармацевтический препарат матричного типа |
| WO2009118764A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
-
2009
- 2009-05-11 AR ARP090101693A patent/AR071706A1/es unknown
- 2009-05-12 PE PE2014000196A patent/PE20140962A1/es not_active Application Discontinuation
- 2009-05-12 PE PE2009000651A patent/PE20091900A1/es not_active Application Discontinuation
- 2009-05-14 CN CN201510411765.9A patent/CN104971037A/zh active Pending
- 2009-05-14 UA UAA201015072A patent/UA102547C2/uk unknown
- 2009-05-14 WO PCT/JP2009/059300 patent/WO2009139504A2/en not_active Ceased
- 2009-05-14 NZ NZ588794A patent/NZ588794A/en not_active IP Right Cessation
- 2009-05-14 KR KR1020107028058A patent/KR101585280B1/ko active Active
- 2009-05-14 CL CL2009001183A patent/CL2009001183A1/es unknown
- 2009-05-14 AU AU2009247156A patent/AU2009247156B2/en not_active Ceased
- 2009-05-14 EP EP09746710.4A patent/EP2273981B1/en active Active
- 2009-05-14 RS RS20150078A patent/RS53775B1/sr unknown
- 2009-05-14 EA EA201071309A patent/EA022712B1/ru not_active IP Right Cessation
- 2009-05-14 SI SI200931076T patent/SI2273981T1/sl unknown
- 2009-05-14 DK DK09746710.4T patent/DK2273981T3/en active
- 2009-05-14 CA CA2722244A patent/CA2722244C/en not_active Expired - Fee Related
- 2009-05-14 MX MX2010012432A patent/MX2010012432A/es active IP Right Grant
- 2009-05-14 JP JP2010545310A patent/JP5552434B2/ja not_active Expired - Fee Related
- 2009-05-14 BR BRPI0912656A patent/BRPI0912656A2/pt not_active IP Right Cessation
- 2009-05-14 TW TW098115963A patent/TWI501789B/zh not_active IP Right Cessation
- 2009-05-14 PT PT97467104T patent/PT2273981E/pt unknown
- 2009-05-14 MY MYPI20104928 patent/MY153109A/en unknown
- 2009-05-14 CN CN2009801173931A patent/CN102119024A/zh active Pending
- 2009-05-14 US US12/992,187 patent/US20110091535A1/en not_active Abandoned
- 2009-05-14 ES ES09746710.4T patent/ES2524261T3/es active Active
- 2009-05-14 PL PL09746710T patent/PL2273981T3/pl unknown
- 2009-05-14 SG SG2013035688A patent/SG190643A1/en unknown
- 2009-05-14 HR HRP20141134AT patent/HRP20141134T1/hr unknown
-
2010
- 2010-10-18 IL IL208788A patent/IL208788A/en not_active IP Right Cessation
- 2010-11-12 ZA ZA2010/08115A patent/ZA201008115B/en unknown
- 2010-11-19 CO CO10145075A patent/CO6321223A2/es not_active Application Discontinuation
- 2010-12-15 EC EC2010010683A patent/ECSP10010683A/es unknown
-
2015
- 2015-01-28 CY CY20151100087T patent/CY1115955T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2529725T3 (es) | Combinaciones de principios activos nematicidas que comprenden fluopiram y Metarhizium | |
| CL2009001183A1 (es) | Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico. | |
| NO20073601L (no) | Immunresponsmodifikator-skumformuleringer | |
| UA94942C2 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| BR112014017749A8 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
| CL2015001959A1 (es) | (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos | |
| BRPI0414581C1 (pt) | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto | |
| DOP2012000011A (es) | Formulacion farmaceutica | |
| EP2078731A4 (en) | ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE | |
| EA201071218A1 (ru) | Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью | |
| EA201270590A1 (ru) | Ингибиторы акт | |
| NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| CL2011000583A1 (es) | Composicion plaguicida que comprende un derivado del ácido alfa-alcoxifenil-acetico y un compuesto neonicotenoide. | |
| BR112012024428A2 (pt) | composição farmacêutica de dissolução rápida | |
| WO2011161396A3 (en) | Disinfectant composition | |
| BR112012007798A2 (pt) | microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas | |
| EP2351753A4 (en) | PHENANTHROINDOLICIDIN DERIVATIVES AND THESE ACTIVE NF-kB-INHIBITORS | |
| BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
| DK1994926T3 (da) | Valsartanformuleringer | |
| MX349563B (es) | Formulacion farmaceutica de fenofibrato nanonizado. | |
| BRPI1006262A2 (pt) | composição que compreende um sistema tensoativo um amido modificado e um ingrediente ativo hidrofóbico e metodo de fabricação de composições | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| NO20073757L (no) | Topiske vaginale farmasoytiske sammensetninger | |
| WO2014065640A3 (ko) | 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물 |